论文部分内容阅读
[目的]检测单核细胞趋化蛋白1(MCP-1)在结直肠癌患者血清中的含量,分析其在结直肠癌患者肝脏转移诊断和预后判断中的应用潜力和价值。[方法]采用ELISA方法定量检测60例健康人员及155例有随访资料的结直肠癌患者血清MCP-1水平,采用SPSS17.0软件进行数据检测分析。[结果]结直肠癌患者血清MCP-1平均水平为260.7±111.4pg/ml,明显高于正常人血清中的188.4±80.4pg/ml(P<0.001)。在结直肠癌组中发生肝脏转移的患者血清MCP-1平均水平为347.7±118.7pg/ml,显著高于无肝脏转移患者平均水平228.4±89.6pg/ml(P<0.001)。Kaplan-Meier生存分析显示,血清MCP-1低表达患者(<251.9pg/ml)的中位生存期为53个月,而血清MCP-1高表达患者(>251.9pg/ml)的中位生存期仅为46个月;前者的3年总生存率为87.9%,而后者仅为54.7%(P<0.001)。Cox比例风险回归模型分析显示,血清MCP-1水平可作为判断结直肠癌患者预后的独立因素(HR=1.528,95%CI:1.093～2.135;P=0.013)。[结论]结直肠癌患者血清MCP-1水平明显高于正常人。发生肝脏转移的结直肠癌患者血清MCP-1水平明显高于无肝脏转移患者。血清MCP-1在结直肠癌及其肝脏转移诊断中具有作为辅助诊断指标的应用潜力。同时血清MCP-1可作为结直肠癌患者预后判断的独立因素,具有重要的临床应用价值。
[Objective] To detect the content of monocyte chemoattractant protein-1 (MCP-1) in the serum of colorectal cancer patients and analyze its potential and value in the diagnosis and prognosis of liver metastasis of patients with colorectal cancer. [Method] The level of serum MCP-1 in 60 healthy individuals and 155 patients with colorectal cancer with follow-up data was detected by ELISA. The data were analyzed by SPSS17.0 software. [Results] The average level of serum MCP-1 in patients with colorectal cancer was 260.7 ± 111.4pg / ml, which was significantly higher than 188.4 ± 80.4pg / ml in normal human serum (P <0.001). The average level of serum MCP-1 in patients with liver metastases in colorectal cancer group was 347.7 ± 118.7 pg / ml, which was significantly higher than the average level of 228.4 ± 89.6 pg / ml in patients without liver metastasis (P <0.001). Kaplan-Meier survival analysis showed a median survival of 53 months in patients with low serum MCP-1 expression (<251.9 pg / ml) and a median survival of> 251.9 pg / ml in patients with high serum MCP-1 expression The duration was only 46 months; the former’s 3-year overall survival was 87.9%, while the latter was only 54.7% (P <0.001). Cox regression analysis showed that serum MCP-1 level could be used as an independent predictor of prognosis in patients with colorectal cancer (HR = 1.528, 95% CI: 1.093-2.13 5; P = 0.013). [Conclusion] The serum level of MCP-1 in patients with colorectal cancer is obviously higher than that in normal people. The serum level of MCP-1 in colorectal cancer patients with liver metastases was significantly higher than those without liver metastases. Serum MCP-1 has potential as a diagnostic marker in the diagnosis of colorectal cancer and its liver metastases. At the same time serum MCP-1 can be used as an independent prognostic factor in patients with colorectal cancer, has important clinical value.